Captor Therapeutics Spolka Akcyjna
WSE:CTX.WA
105 (PLN) • At close December 14, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) PLN.
| 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2.954 | 3.53 | 4.836 | 4.505 | 6.485 | 2.814 | 2.359 | 1.543 | 5.821 | 1.11 | 1.191 | 1.036 | 1.279 | 1.253 | 1.03 | 0.424 | 0 | 0 |
| Cost of Revenue
| 2.147 | 1.126 | 1.403 | 1.521 | 4.993 | 1.76 | -0.162 | 0.433 | 0.958 | 0.544 | 0.303 | 0.282 | 0.259 | 0.482 | 0 | 0 | 0 | 0.007 |
| Gross Profit
| 0.807 | 2.404 | 3.433 | 2.984 | 1.492 | 1.054 | 2.521 | 1.11 | 4.863 | 0.566 | 0.888 | 0.754 | 1.02 | 0.771 | 1.03 | 0.424 | 0 | -0.007 |
| Gross Profit Ratio
| 0.273 | 0.681 | 0.71 | 0.662 | 0.23 | 0.375 | 1.069 | 0.719 | 0.835 | 0.51 | 0.746 | 0.728 | 0.797 | 0.615 | 1 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 7.524 | 10.316 | 9.223 | 10.006 | 14.099 | 15.384 | 21.444 | 13.45 | 23.448 | 5.904 | 8.299 | 6.504 | 6.475 | 6.45 | 5.489 | 4.702 | 4.691 | 6.302 |
| General & Administrative Expenses
| 0 | 2.404 | 3.342 | 2.608 | 2.641 | 5.098 | 4.094 | 4.304 | 2.508 | 5.615 | 5.394 | 6.041 | 5.365 | 5.777 | 4.634 | 3.769 | 1.216 | 1.689 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 1.391 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.264 | 2.404 | 3.342 | 2.608 | 4.032 | 5.098 | 4.094 | 4.304 | 2.508 | 5.615 | 5.394 | 6.041 | 5.365 | 5.777 | 4.634 | 3.769 | 1.216 | 1.689 |
| Other Expenses
| 0 | 0 | 0.99 | 0 | 0 | 0 | 0 | -1.188 | -12.899 | -1.633 | -2.808 | -0.938 | -0.01 | -1.557 | -3.308 | -2.833 | -4.409 | -1.76 |
| Operating Expenses
| 11.788 | 12.741 | 13.555 | 12.706 | 18.131 | 17.321 | 32.242 | 16.566 | 13.057 | 9.886 | 10.885 | 11.607 | 11.83 | 10.67 | 6.815 | 5.638 | 1.498 | 6.231 |
| Operating Income
| -10.981 | -10.337 | -10.122 | -9.722 | -16.639 | -16.267 | -29.72 | -15.456 | -8.194 | -9.32 | -9.997 | -10.853 | -10.811 | -8.768 | -6.916 | -5.214 | -1.498 | -6.231 |
| Operating Income Ratio
| -3.717 | -2.928 | -2.093 | -2.158 | -2.566 | -5.781 | -12.599 | -10.017 | -1.408 | -8.396 | -8.394 | -10.476 | -8.453 | -6.998 | -6.715 | -12.297 | 0 | 0 |
| Total Other Income Expenses Net
| 2.221 | 0.095 | 0.138 | 0.282 | 0.086 | 0.492 | 0.684 | 1.227 | 1.679 | 0.781 | 0.133 | -0.123 | -0.091 | -0.102 | -0.557 | -0.114 | -0.095 | -0.08 |
| Income Before Tax
| -8.76 | -10.242 | -9.984 | -9.44 | -11.486 | -15.775 | -29.036 | -14.23 | -6.515 | -8.539 | -9.864 | -10.976 | -10.902 | -8.87 | -7.473 | -5.328 | -1.593 | -6.311 |
| Income Before Tax Ratio
| -2.965 | -2.901 | -2.065 | -2.095 | -1.771 | -5.606 | -12.309 | -9.222 | -1.119 | -7.693 | -8.282 | -10.595 | -8.524 | -7.079 | -7.255 | -12.566 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0.341 | 1.092 | 0.557 | 0.057 | -1.226 | -1.679 | -0.781 | -0.133 | 0.123 | 0.076 | -1.147 | 0.713 | -0.015 | 0.004 | -0.012 |
| Net Income
| -8.76 | -10.242 | -9.984 | -9.44 | -11.486 | -15.775 | -29.093 | -13.004 | -4.836 | -7.758 | -9.731 | -11.099 | -10.902 | -8.87 | -7.474 | -5.327 | -1.593 | -6.311 |
| Net Income Ratio
| -2.965 | -2.901 | -2.065 | -2.095 | -1.771 | -5.606 | -12.333 | -8.428 | -0.831 | -6.989 | -8.17 | -10.713 | -8.524 | -7.079 | -7.256 | -12.564 | 0 | 0 |
| EPS
| -1.59 | -2.19 | -2.14 | -2.04 | -2.47 | -3.72 | -6.91 | -3.09 | -1.16 | -1.86 | -2.36 | -2.69 | -2.64 | -2.15 | -1.81 | -1.64 | -0.49 | -1.94 |
| EPS Diluted
| -1.59 | -2.2 | -2.14 | -2.04 | -2.47 | -3.72 | -6.91 | -3.09 | -1.16 | -1.85 | -2.36 | -2.69 | -2.64 | -2.15 | -1.81 | -1.64 | -0.49 | -1.94 |
| EBITDA
| -7.512 | -8.646 | -8.536 | -8.235 | -10.276 | -14.494 | -27.629 | -12.527 | -6.588 | -6.841 | -7.869 | -8.954 | -9.011 | -8.057 | -6.547 | -3.407 | 0.349 | -6.236 |
| EBITDA Ratio
| -2.543 | -2.449 | -1.765 | -1.828 | -1.585 | -5.151 | -11.712 | -8.119 | -1.132 | -6.163 | -6.607 | -8.643 | -7.045 | -6.43 | -6.356 | -8.035 | 0 | 0 |